{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:36:21Z","timestamp":1790706981465,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"DOI":"10.1093\/jjco\/hyi111","type":"journal-article","created":{"date-parts":[[2005,6,23]],"date-time":"2005-06-23T20:39:12Z","timestamp":1119559152000},"page":"395-399","source":"Crossref","is-referenced-by-count":15,"title":["Long-term Outcome of a Low-dose Intravesical Bacillus Calmette\u2013Guerin Therapy for Carcinoma In Situ of the Bladder: Results After Six Successive Instillations of 40 mg BCG"],"prefix":"10.1093","volume":"35","author":[{"given":"Soichi","family":"Mugiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Hadano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,6,23]]},"reference":[{"key":"key\n\t\t\t\t20171013012705_B1","doi-asserted-by":"crossref","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette\u2013Guerin in the treatment of superficial bladder tumor. J Urol1976;116:180\u20133.","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"key\n\t\t\t\t20171013012705_B2","doi-asserted-by":"crossref","unstructured":"Ovesen H, Poulsen A, Steven K. Intravesical bacillus Calmette\u2013Guerin with the Danish strain for treatment of carcinoma in situ of the bladder. Br J Urol1993;72:744\u20138.","DOI":"10.1111\/j.1464-410X.1993.tb16260.x"},{"key":"key\n\t\t\t\t20171013012705_B3","unstructured":"Lamm DL. BCG immunotherapy for transitional cell carcinoma in situ of the bladder. Oncology1995;9:947\u201365."},{"key":"key\n\t\t\t\t20171013012705_B4","doi-asserted-by":"crossref","unstructured":"Akaza H, Hinostu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette\u2013Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer1995;75:552\u20139.","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H"},{"key":"key\n\t\t\t\t20171013012705_B5","doi-asserted-by":"crossref","unstructured":"Akaza H, Kameyama S, Koiso K, Kakizoe T, Kojima H, Umeda T, et al. Analyses of the effects of intravesical bacillus Calmette\u2013Guerin (Tokyo 172 strain) therapy for superficial bladder cancer. Nippon Hinyokika Gakkai Zasshi1989;80:167\u201374 (in Japanese).","DOI":"10.5980\/jpnjurol1989.80.167"},{"key":"key\n\t\t\t\t20171013012705_B6","doi-asserted-by":"crossref","unstructured":"Kudo S, Tsushima N, Sawada Y, Saito F, Motomura F, Takashima T, et al. Serious complications of intravesical bacillus Calmette\u2013Guerin therapy in patients with bladder cancer. Nippon Hinyokika Gakkai Zasshi1991;82:1594\u2013602 (in Japanese).","DOI":"10.5980\/jpnjurol1989.82.1594"},{"key":"key\n\t\t\t\t20171013012705_B7","doi-asserted-by":"crossref","unstructured":"Takashi M, Wakai K, Ohno Y, Murase T, Miyake K. Evaluation of a low-dose intravesical bacillus Calmette\u2013Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol1995;27:723\u201333.","DOI":"10.1007\/BF02552138"},{"key":"key\n\t\t\t\t20171013012705_B8","doi-asserted-by":"crossref","unstructured":"Irie A, Uchida T, Yamashita H, Matsumoto K, Satoh T, Koh H, et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette\u2013Guerin for superficial bladder cancer recurrence. Int J Urol2003;10:183\u20139.","DOI":"10.1046\/j.0919-8172.2003.00607.x"},{"key":"key\n\t\t\t\t20171013012705_B9","doi-asserted-by":"crossref","unstructured":"Kurth KH, Schellhammer PF, Okajima E, Akdas A, Jakse G, Herr HW, et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol1995;2:8\u201322.","DOI":"10.1111\/j.1442-2042.1995.tb00475.x"},{"key":"key\n\t\t\t\t20171013012705_B10","unstructured":"Japanese Urological Association and Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer, 3rd edn. Tokyo: Kanehara Shuppann 2001 (in Japanese)."},{"key":"key\n\t\t\t\t20171013012705_B11","doi-asserted-by":"crossref","unstructured":"Lamm DL, Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette\u2013Guerin intravesical therapy in superficial bladder cancer. J Urol1992;147:596\u2013600.","DOI":"10.1016\/S0022-5347(17)37316-0"},{"key":"key\n\t\t\t\t20171013012705_B12","doi-asserted-by":"crossref","unstructured":"Akaza H, Kameyama S, Kakizoe T, Kojima H, Koiso K, Aso Y, et al. Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Nippon Hinyokika Gakkai Zasshi1992;83:183\u20139 (in Japanese).","DOI":"10.5980\/jpnjurol1989.83.183"},{"key":"key\n\t\t\t\t20171013012705_B13","doi-asserted-by":"crossref","unstructured":"Ikeda N, Honda I, Yano I, Koyama A, Toida I. Bacillus Camette\u2013Guerin Tokyo 172 substrain for superficial bladder carcinoma: characterization and antitumor effect. J Urol2005;173:1507\u201312.","DOI":"10.1097\/01.ju.0000154354.06892.ba"},{"key":"key\n\t\t\t\t20171013012705_B14","unstructured":"Ozono S, Takahashi K, Tanaka N, Momose H, Hirao Y, Okajima E, et al. Intravesical bacillus Calmette\u2013Guerin (BCG) therapy for carcinoma in situ of the urinary bladder\u2014outcomes of a randomized study. Ann Soc BCG BRM Immunother1996;20:95\u2013100 (in Japanese)."},{"key":"key\n\t\t\t\t20171013012705_B15","unstructured":"Okaneya T, Ikado S, Murata Y, Niwakawa M, Mizusawa H, Yamaguchi K, et al. Intravesical bacillus Calmette\u2013Guerin instillation for in situ and superficial bladder carcinoma: results of ten successive instillations of 40 milligrams. Jpn J Clin Urol1991;45:129\u201332 (in Japanese)."},{"key":"key\n\t\t\t\t20171013012705_B16","unstructured":"Okaneya T, Komiyama M, Niwakawa M, Murata Y, Nishizawa O. Long-term outcome of intravesical bacillus Calmette\u2013Guerin instillation for bladder carcinoma: results of 8 to 14 successive instillation of 40 mg BCG for treatment or prophylaxis. Ann Soc BCG BRM Immunother1999;23:71\u20135 (in Japanese)."},{"key":"key\n\t\t\t\t20171013012705_B17","doi-asserted-by":"crossref","unstructured":"Takashi M, Katsuno S, Yuba H, Ohshima S, Wakai K, Ohno Y. Possible factors affecting response to intravesical bacillus Calmette\u2013Guerin (Tokyo 172 Strain) therapy for carcinoma in situ of the bladder. Int Urol Nephrol1998;30:713\u201322.","DOI":"10.1007\/BF02564859"},{"key":"key\n\t\t\t\t20171013012705_B18","doi-asserted-by":"crossref","unstructured":"Harada Y, Seguchi T, Nonomura N, Kojima Y, Miki T, Okuyama A. Clinical study of carcinoma in situ of the urinary bladder. Nippon Hinyokika Gakkai Zasshi1998;89:693\u20137 (in Japanese).","DOI":"10.5980\/jpnjurol1989.89.693"},{"key":"key\n\t\t\t\t20171013012705_B19","unstructured":"Ozono S, Kagebayashi Y, Yamamoto H, Mibu H, Horikawa N, Hirayama A, et al. Methods to evaluate response to BCG instillation therapy for CIS. Ann Soc BCG BRM Immunother2000;24:55\u20139 (in Japanese)."},{"key":"key\n\t\t\t\t20171013012705_B20","doi-asserted-by":"crossref","unstructured":"Losa A, Hurle R, Lembo A. Low dose bacillus Calmette\u2013Guerin for carcinoma in situ of the bladder: long-term results. J Urol2000;163:68\u201372.","DOI":"10.1016\/S0022-5347(05)67974-8"},{"key":"key\n\t\t\t\t20171013012705_B21","doi-asserted-by":"crossref","unstructured":"Koga H, Kuroda M, Kudo S, Yamaguchi A, Usami M, Suzuki T, et al. Adverse drug reactions of intravesical bacillus Calmette\u2013Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int J Urol2005;12:145\u201351.","DOI":"10.1111\/j.1442-2042.2005.01000.x"},{"key":"key\n\t\t\t\t20171013012705_B22","unstructured":"Lamm DL. BCG immunotherapy for transitional cell carcinoma in situ of the bladder. Oncology1995;9:947\u201365."}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/35\/7\/395\/5213421\/hyi111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T01:27:27Z","timestamp":1507858047000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jjco\/article\/35\/7\/395\/878827\/Longterm-Outcome-of-a-Lowdose-Intravesical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,23]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2005,6,23]]},"published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyi111","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"value":"1465-3621","type":"electronic"},{"value":"0368-2811","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,7]]},"published":{"date-parts":[[2005,6,23]]}}}